Athena Neurosciences Inc. acquires Exemplar Technology.SOUTH SAN FRANCISCO South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , Calif.--(BUSINESS WIRE)--Dec. 5, 1994-- Athena Neurosciences Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ATHN) announced Monday that, in addition to its internal efforts to develop transgenic animal Transgenic animal Animals that have had genes from other species inserted into their genetic code. Mentioned in: Glycogen Storage Diseases models for Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. , it has executed an agreement to acquire substantially all of the assets of Exemplar Corp., a privately held corporation Noun 1. privately held corporation - a corporation owned by a few people; shares have no public market close corporation, closed corporation, private corporation located in Waltham, Mass. In return for 420,000 shares of Athena Common Stock and a cash payment of $100,000, Athena will acquire all of Exemplar's technology, assets and rights which relate to the research and development of in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment. in vi·tro adj. In an artificial environment outside a living organism. and in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body. in vi·vo adj. Within a living organism. in vivo adv. screens, including animal models for pharmaceutical testing. In addition to transgenic models for Alzheimer's disease, Exemplar was developing transgenic models for use in the areas of AIDS, oncology and genetic toxicology. The consummation of the asset purchase is subject, among other things, to the effectiveness of a Registration Statement to be filed with the Securities and Exchange Commission covering the issuance of the shares of Athena Common Stock and approval of the asset purchase by Exemplar's stockholders. Athena and Exemplar concurrently entered into an exclusive license agreement whereby Exemplar granted Athena a worldwide, exclusive license to develop, use and sell any animal or cell line derived from transgenic cell lines developed by Exemplar that is useful in the field of human neurological diseases or conditions, including Alzheimer's disease. If the asset acquisition is not consummated, the license agreement will remain in effect. The license agreement calls for specified payments to be made under certain defined conditions. Further details of the terms of this license agreement were not disclosed. Athena Neurosciences Inc. was founded in 1986 to discover, develop and market products to be used primarily by neurologists for the treatment and diagnosis of neurological diseases and disorders. CONTACT: Athena Neurosciences Inc., South San Francisco John Groom, 415/877-0900 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion